InflaRx N.V. logo

InflaRx N.V. (IF0)

Market Open
4 Jul, 20:00
0. 70
+0.02
+3.1%
- Market Cap
- P/E Ratio
0% Div Yield
500 Volume
- Eps
0.68
Previous Close
Day Range
0.68 0.7
Year Range
0.62 2.61
Want to track IF0 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 30 days

Summary

IF0 trading today higher at €0.7, an increase of 3.1% from yesterday's close, completing a monthly increase of 5.35% or €0.04. Over the past 12 months, IF0 stock lost -70.93%.
IF0 is not paying dividends to its shareholders.
The last earnings report, released on May 07, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on Aug 06, 2025.
The stock of the company had never split.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).

IF0 Chart

Chart

Empty chart
The chart has 2 Y axes displaying values, and values.
Loading, please wait...
End of interactive chart.
InflaRx to Participate in Upcoming Investor Conferences

InflaRx to Participate in Upcoming Investor Conferences

JENA, Germany, May 22, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will participate in multiple investor conferences in June and July 2025.

Globenewswire | 1 month ago
InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update

InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update

JENA, Germany, May 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its financial results for the three months ended March 31, 2025, and provided a business update.

Globenewswire | 2 months ago
InflaRx to Report First Quarter 2025 Results on May 7, 2025

InflaRx to Report First Quarter 2025 Results on May 7, 2025

JENA, Germany, April 30, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will report its first quarter 2025 financial and operating results on May 7, 2025, before the market opens. No conference call is planned.

Globenewswire | 2 months ago

InflaRx N.V. Dividends

IF0 is not paying dividends to its shareholders.

InflaRx N.V. Earnings

7 Aug 2025 (In 1 month) Date
-
Cons. EPS
-
EPS
6 Aug 2025 (In 1 month) Date
-
Cons. EPS
-
EPS
7 May 2025 Date
-
Cons. EPS
-
EPS
8 Aug 2024 Date
-
Cons. EPS
-
EPS
8 May 2024 Date
-
Cons. EPS
-
EPS
IF0 is not paying dividends to its shareholders.
7 Aug 2025 (In 1 month) Date
-
Cons. EPS
-
EPS
6 Aug 2025 (In 1 month) Date
-
Cons. EPS
-
EPS
7 May 2025 Date
-
Cons. EPS
-
EPS
8 Aug 2024 Date
-
Cons. EPS
-
EPS
8 May 2024 Date
-
Cons. EPS
-
EPS

InflaRx N.V. (IF0) FAQ

What is the stock price today?

The current price is €0.70.

On which exchange is it traded?

InflaRx N.V. is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is IF0.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, no market cap data is available.

When is the next earnings date?

The next earnings report will release on Aug 06, 2025.

Has InflaRx N.V. ever had a stock split?

No, there has never been a stock split.

InflaRx N.V. Profile

Biotechnology Industry
Healthcare Sector
Niels C. Riedemann CEO
XSTU Exchange
NL0012661870 ISIN
DE Country
74 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

InflaRx N.V. is a clinical-stage biopharmaceutical company based in Jena, Germany, with operations extending to the United States, focused on the discovery and development of inhibitors leveraging its proprietary C5a technology. Founded in 2007, originally as Fireman B.V., the company underwent a rebranding to InflaRx N.V. in 2017. It specializes in targeting C5a, a key inflammatory mediator implicated in a range of autoimmune and inflammatory diseases. InflaRx's innovative approach aims to mitigate the progression of these diseases by inhibiting the action of C5a. The company engages in significant collaborations, including a co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. and a clinical trial collaboration and supply agreement with Merck & Co. Inc., underscoring its commitment to advancing its pipeline of treatments through strategic partnerships.

Products and Services

  • Vilobelimab:

    An intravenously administered first-in-class anti-C5a monoclonal antibody. Vilobelimab has completed a Phase III clinical trial for the treatment of hidradenitis suppurativa, a chronic inflammatory skin disease. It is also undergoing Phase II trials for anti-neutrophil cytoplasm antibody-associated vasculitis, a severe autoimmune disease; a Phase IIa exploratory study for pyoderma gangraenosum, another chronic inflammatory skin disorder; and a Phase II trial for PD-1/PD-L1 inhibitor-resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma.

  • INF904:

    An oral, small molecule drug candidate designed for the management of chronic inflammatory and autoimmune diseases. Currently under development, INF904 represents InflaRx's efforts to expand its portfolio into oral therapeutics for wider applications in autoimmunity and inflammation.

  • IFX002:

    This candidate is in the pre-clinical development stage and seeks to offer a new treatment option for chronic inflammation and autoimmune diseases. IFX002 illustrates InflaRx's commitment to diversifying its strategies against inflammatory mediators beyond its flagship C5a technology.

  • Gohibic (vilobelimab) for COVID-19 and broader ARDS:

    A specialized application of vilobelimab, targeting the treatment of COVID-19 and broader Acute Respiratory Distress Syndrome (ARDS). In this context, InflaRx aims to address the inflammatory component of these respiratory conditions, reflecting the company's adaptability in applying its technologies to emergent global health challenges.

Contact Information

Address: Winzerlaer Str. 2
Phone: 49 3641 508 180